ArticleInternational journal of cardiology. Congenital heart disease2022
Diuretic use in the adult Fontan.
Article in International journal of cardiology. Congenital heart disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore diuretic use in Fontan patients and its association with clinical features and adverse outcomes. Background: In Fontan circulatory failure, ventricular dysfunction, chronically elevated systemic venous pressures, lymphatic abnormalities, and preload deprivation lead to volume expansion, prompting initiation of diuretics, yet use of diuretics has not been widely studied in the adult Fontan patient. Methods: Single center retrospective review of Fontan patients ≥18 years between 2005 and 2018. Descriptive statistics compared Fontan patients by diuretic. Univariate logistic regression analyses were performed. Variables with a p value < 0.05 were selected to create multivariable model using backwards stepwise regression. Kaplan-Meier product-limit estimates stratified by diuretic use were used to find estimates of transplant and death rates. Log-rank tests were used to compare the time to outcome by diuretic use and Cox Proportional Hazards models examined the risk of transplant or death based on diuretic use. Results: Of 206 Fontan patients, 96 (47%) were taking diuretics. Multivariable analysis demonstrated the following associated with diuretic use: age (Adjusted Odds Ratio [AOR] 1.06; p = 0.02); cyanosis (AOR 3.59; p=<0.01); tachyarrhythmia (AOR 2.64; p=<0.01); pacemaker (AOR 2.48; p = 0.02); ≥ moderate atrioventricular (AV) valve regurgitation (AOR 2.88; p=<0.05); New York Heart Association Class II-IV (AOR 3.41; p < 0.01). Diuretic use was associated with a 17-fold increased risk of transplant or death (95% CI 2.3-131.9; p=<0.01). Conclusion: Diuretic use is common in adult Fontan patients. Multiple clinical correlates of heart failure were associated with diuretic use. Transplant-free survival was significantly reduced in those taking diuretics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.